Integrated DNA Technologies moved into the in vitro diagnostics market with two IVD next‑generation sequencing library‑preparation assays: Archer FusionPlex‑HT Dx and Archer VariantPlex‑HT Dx. IDT, a Danaher subsidiary, acquired the Archer portfolio from Invitae in 2022 and said the IVD launch is aimed at clinical labs facing shifting regulation such as Europe’s IVDR and changing US requirements. The assays use patented anchored multiplex PCR chemistry to handle degraded FFPE inputs and are positioned against competitors including Illumina and Twist Biosciences in the clinical oncology testing space.